Innovative molecules and compelling combinations

Preclinical
Phase 1
Phase 2
Phase 3
Status

EOS-984: Small molecule targeting ENT1

  • Monotherapy
  • +pembrolizumab
  • Solid tumors

APT-008

Data Anticipated 2H25

EOS-215: mAb targeting TREM2

  • Monotherapy
  • +pembrolizumab
  • Solid tumors

TRM-010

Enrolling